BIOCRYST PHARMACEUTICALS INC Quarterly Costs and Expenses in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Biocryst Pharmaceuticals Inc quarterly/annual Costs and Expenses history and growth rate from Q2 2010 to Q3 2024.
  • Biocryst Pharmaceuticals Inc Costs and Expenses for the quarter ending September 30, 2024 was $109M, a 10.9% increase year-over-year.
  • Biocryst Pharmaceuticals Inc Costs and Expenses for the twelve months ending September 30, 2024 was $453M, a 6.68% increase year-over-year.
  • Biocryst Pharmaceuticals Inc annual Costs and Expenses for 2023 was $435M, a 3.78% increase from 2022.
  • Biocryst Pharmaceuticals Inc annual Costs and Expenses for 2022 was $419M, a 25.2% increase from 2021.
  • Biocryst Pharmaceuticals Inc annual Costs and Expenses for 2021 was $335M, a 73.9% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $453M $109M +$10.7M +10.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $443M $101M -$2.62M -2.54% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $445M $107M +$10.1M +10.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $435M $136M +$10.2M +8.12% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $425M $98.7M +$5.39M +5.78% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $420M $103M +$2.94M +2.93% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $417M $97.2M -$2.69M -2.69% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $419M $126M +$26.5M +26.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $393M $93.3M +$7.69M +8.99% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $385M $100M +$20.7M +26% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $364M $99.9M +$29.4M +41.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $335M $99.3M +$42.9M +76.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $292M $85.6M +$36.6M +74.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 $255M $79.5M +$38.2M +92.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 $217M $70.4M +$24.6M +53.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $193M $56.4M +$16.6M +41.6% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 $176M $49M +$12.1M +32.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $164M $41.4M +$5.02M +13.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $159M $45.8M +$10.6M +30.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $148M $39.8M +$11.8M +42.3% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $136M $36.9M +$6.93M +23.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $130M $36.4M +$5.62M +18.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $124M $35.2M +$9.03M +34.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $115M $28M +$6.24M +28.7% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 $109M $29.9M +$7.84M +35.5% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $101M $30.7M +$12.1M +65.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $88.7M $26.2M +$6.07M +30.2% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $82.6M $21.8M +$4.58M +26.7% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-13
Q3 2017 $78M $22.1M +$5.11M +30% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $72.9M $18.6M +$1.7M +10% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $71.2M $20.1M -$3.75M -15.7% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $75M $17.2M -$4.63M -21.2% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-14
Q3 2016 $79.6M $17M -$7.15M -29.6% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $86.7M $16.9M -$3.58M -17.5% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 $90.3M $23.9M +$2.61M +12.3% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-08
Q4 2015 $87.7M $21.8M +$1.19M +5.8% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-12
Q3 2015 $86.5M $24.1M +$9.3M +62.6% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-08
Q2 2015 $77.2M $20.5M +$7.42M +56.7% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 $69.8M $21.3M +$10.4M +96% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-09
Q4 2014 $59.4M $20.6M +$3.7M +21.9% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-27
Q3 2014 $55.7M $14.8M +$5.53M +59.4% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q2 2014 $50.1M $13.1M +$122K +0.94% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-07
Q1 2014 $50M $10.8M +$1.97M +22.3% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q4 2013 $48M $16.9M +$2.11M +14.2% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-26
Q3 2013 $45.9M $9.31M -$4.46M -32.4% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-07
Q2 2013 $50.4M $13M -$1.42M -9.89% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-08
Q1 2013 $51.8M $8.87M -$8.35M -48.5% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-09
Q4 2012 $60.2M $14.8M -$1.47M -9.03% Oct 1, 2012 Dec 31, 2012 10-K 2015-03-02
Q3 2012 $61.6M $13.8M -$4.28M -23.7% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-08
Q2 2012 $65.9M $14.4M -$3.59M -20% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-08
Q1 2012 $69.5M $17.2M +$288K +1.7% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-09
Q4 2011 $69.2M $16.3M Oct 1, 2011 Dec 31, 2011 10-K 2014-03-10
Q3 2011 $18.1M -$4.94M -21.5% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-08
Q2 2011 $18M +$32K +0.18% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-08
Q1 2011 $16.9M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-08
Q3 2010 $23M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-03
Q2 2010 $17.9M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.